Novartis Ilaris to be the first FDA approved treatment for Adult-Onset Still’s Disease (AOSD)

FDA approved Novartis Cosentyx and Lilly’s Taltz for nr-axSpA in June

Viela Bio’s Uplizna received FDA approval for neuromyelitis optica spectrum disorder

Opdivo approved in the US for ESCC

Taltz was approved in the U.S. for non-radiographic axial spondyloarthritis

FDA approved Merck’s Recarbrio to treat hospital acquired pneumonia

Gilead announced the positive Phase 3 trial of remdesivir in COVID-19 patients

Deciphera Pharmaceuticals’ Qinlock (ripretinib) received the US FDA approval for advanced GIST

FDA approved Novartis’ Tabrecta for NSCLC with METex14

PFIZER AND BIONTECH STARTS THE CLINICAL TRIALS OF COVID-19 VACCINE

AstraZeneca’s approved Koselugo by US FDA for neurofibromatosis type 1

FDA approved a new treatment for a rare soft tissue cancer, epithelioid sarcoma

Trump administration takes first step in implementing provisional law to control drug prices

AstraZeneca’s Farxiga received fast track designation from US FDA

Novartis capmatinib (INC280) received breakthrough designation by FDA

FDA approved Kyowa Kirin’s Nourianz for adults with Parkinson’s disease

FDA approved AbbVie’s Rinvoq for treatment of moderately to severe rheumatoid arthritis